View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 21, 2009

Tekturna Approved as Alternative to Multiple Blood Pressure Drugs

The US Food and Drug Administration (FDA) has approved Tekturna HCT tablets from Novartis as an alternative initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals. Tekturna HCT is a single-pill combination of Tekturna (aliskiren) and th

By cms admin

The US Food and Drug Administration (FDA) has approved Tekturna HCT tablets from Novartis as an alternative initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals.

Tekturna HCT is a single-pill combination of Tekturna (aliskiren) and the diuretic hydrochlorothiazide (HCTZ), one of the most commonly used high blood pressure medications.

The FDA granted approval based on clinical trials involving more than 2,700 patients, which showed that the combination of Tekturna and HCTZ offered greater blood pressure reductions than either drug alone.

Western Pennsylvania Hospital cardiologist and professor of medicine at Temple University Dr Alan Gradman said that this approval gives doctors the opportunity to aggressively treat their patients with a single-pill combination.

“This results in more significant blood pressure reductions, compared to taking either drug alone,” Gradman said.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology